which is contraindicated in many patients. Non-contrast CT (NCCT) is widely accessible but is considered limited for tumor analysis. This study aims to develop and validate a deep learning system for automated renal tumor localization and ccRCC classification using only NCCT. Methods In a multicenter retrospective study of 1
902 patients with paired NCCT and CECT series
expert annotations were propagated to NCCT via 3D hybrid affine and deformable registration. An integrated AI pipeline combining a 3D U-Net for segmentation with three 3D classifiers (ResNet-50
Vision Transformer
Swin Transformer) was developed. Three model configurations (NCCT-only
CECT-only
multiseries fusion) were evaluated using area under the curve (AUC)
accuracy
sensitivity
specificity
and DeLong’s test. Results The NCCT-based segmentation model achieved tumor Dice coefficients approaching the CECT-based model (0.89 ± 0.08 vs. 0.96 ± 0.05 internally). For classification
NCCT models showed performance that was noninferior to that of CECT models
with no significant AUC differences (internal: 0.80 vs. 0.78 for ResNet-50). On the external test set (n = 231)
NCCT model achieved AUCs of 0.76–0.82
which was comparable to the CECT model. The fusion model outperformed the NCCT model using ResNet-50
which consistently surpassed transformer-based architectures. Conclusions This study demonstrates an AI system for accurate renal tumor localization and ccRCC classification directly from NCCT
achieving performance comparable to CECT-based models. This contrast-free approach could enhance accessible renal cancer screening and provide diagnostic support for patients with contraindications to contrast media or in resource-limited settings.
Abstract
Introduction The accurate characterization of renal tumors
which is contraindicated in many patients. Non-contrast CT (NCCT) is widely accessible but is considered limited for tumor analysis. This study aims to develop and validate a deep learning system for automated renal tumor localization and ccRCC classification using only NCCT. Methods In a multicenter retrospective study of 1
902 patients with paired NCCT and CECT series
expert annotations were propagated to NCCT via 3D hybrid affine and deformable registration. An integrated AI pipeline combining a 3D U-Net for segmentation with three 3D classifiers (ResNet-50
Vision Transformer
Swin Transformer) was developed. Three model configurations (NCCT-only
CECT-only
multiseries fusion) were evaluated using area under the curve (AUC)
accuracy
sensitivity
specificity
and DeLong’s test. Results The NCCT-based segmentation model achieved tumor Dice coefficients approaching the CECT-based model (0.89 ± 0.08 vs. 0.96 ± 0.05 internally). For classification
NCCT models showed performance that was noninferior to that of CECT models
with no significant AUC differences (internal: 0.80 vs. 0.78 for ResNet-50). On the external test set (n = 231)
NCCT model achieved AUCs of 0.76–0.82
which was comparable to the CECT model. The fusion model outperformed the NCCT model using ResNet-50
which consistently surpassed transformer-based architectures. Conclusions This study demonstrates an AI system for accurate renal tumor localization and ccRCC classification directly from NCCT
achieving performance comparable to CECT-based models. This contrast-free approach could enhance accessible renal cancer screening and provide diagnostic support for patients with contraindications to contrast media or in resource-limited settings.
From morphology to function: Advances in multimodal imaging for pulmonary function prediction
Deep learning-based segmentation of small-volume brain metastases in lung cancer patients
Multimodal medical imaging AI for breast cancer diagnosis: A comprehensive review
Deep learning-based localization of preoperative parathyroid glands in secondary hyperparathyroidism patients using dual-phase unenhanced and contrast-enhanced computed tomography data
Deep learning in abdominal organ segmentation: A review
Related Author
Shao
Zhou
Niu
Wang
Shi
Hu
Fan
Feng
Related Institution
Santa Clara University, Santa Clara CA
Hangzhou PathoAI Technology Co., Ltd.
University of Strathclyde, Glasgow G1 1QN, United Kingdom